Let’s be real: even with the best intentions, AI systems can reflect our own unconscious biases. As Daniel Kahneman and Amos Tversky famously demonstrated in their groundbreaking work on Prospect Theory, humans are prone to cognitive biases that influence our…
HOME > BUSINESS
BUSINESS
- Takeda Halts PIII Study of Aurora A Kinase Inhibitor for Peripheral T-cell Lymphoma
May 14, 2015
- Blopress AG Gives Lift to ASKA Sales and Profits
May 13, 2015
- Ono’s Operating Profit Declines 40%; NHI Price Reductions, Generics Had Major Negative Impact
May 13, 2015
- Ono to Expand Cancer-Specialized Rep Force to 150 by October Aiming for Additional Indications for Opdivo
May 13, 2015
- Denka Seiken to Start Development of Mass Production Technology for Therapeutic Oncolytic Virus for Cancer Therapy
May 13, 2015
- Ethical Drug Sales Down 5.2% in March: Crecon Report
May 13, 2015
- Shionogi Logs Record Ordinary Profit on Weaker Yen, ViiV Dividends
May 12, 2015
- Sumitomo Dainippon’s Profits Slide as Japan Sales Flounder
May 12, 2015
- Astellas Withdraws NDA for Nateglinide in Combination with DPP-4 Inhibitors
May 12, 2015
- Astellas Earnings Buoyant on Xtandi, Overseas Sales Offset Japan Fall
May 12, 2015
- MTPC Sees Sales Rise for Remicade in FY2015, Mulls M&A under 5-Year Biz Plan
May 11, 2015
- MTPC Sales Up Slightly as Gilenya, Invokana Royalties Eclipse Japan Dip
May 11, 2015
- Takeda, NCC Join Hands on Cancer Drug Research
May 11, 2015
- Takeda to Return Latuda Rights in Europe to Sumitomo Dainippon
May 8, 2015
- Takecab Tops in GP and HP Markets for 3rd Month in a Row in March: Anterio Ranking
May 8, 2015
- Oncolys Initiates PI Trial of Novel Anticancer Drug in Patients with Solid Cancers in the US
May 8, 2015
- US Drug Spending Spikes in 2014 Lifted by Cancer, Hepatitis C Medicines: IMS
May 7, 2015
- PhRMA Member Companies Invest US$51.2 Billion in New Drug R&D in 2014
May 7, 2015
- US Sales of Abilify Rise 2.4% in January-March: Otsuka Holdings
May 7, 2015
- Zeria Cuts FY2014 Forecasts, to Lose 40% of Estimated Profits
May 7, 2015
ページ
As Japan approaches the Fiscal System Council’s “autumn recommendation,” a notable shift is taking shape. The Ministry of Finance (MOF),…
Japan is considering a new approach to its “special” market expansion re-pricing that would exclude drug sales tied to private…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…